Related Experiment Videos
Ebastine in perennial allergic rhinitis
C Picado Vallés1, A Cadahia García, A Cisteró Bahima
1Hospital Clinico Provincial, Barcelona, Spain.
Annals of Allergy
|December 1, 1991
Summary
Oral ebastine effectively treated perennial allergic rhinitis symptoms. This study found ebastine significantly reduced symptom severity and incidence with good tolerability, similar to placebo.
Area of Science:
- Allergy and Immunology
- Pharmacology
- Clinical Medicine
Background:
- Perennial allergic rhinitis (PAR) significantly impacts quality of life.
- Effective and well-tolerated treatments for PAR are needed.
Purpose of the Study:
- To evaluate the efficacy and tolerability of oral ebastine in patients with active PAR.
- To compare ebastine 10 mg once daily against placebo.
Main Methods:
- Multicenter, randomized, double-blind, placebo-controlled trial.
- 151 patients with active PAR were enrolled.
- Treatment duration was seven days with oral ebastine or placebo.
Main Results:
- Ebastine significantly reduced the incidence and severity of most PAR symptoms.
- No significant difference in tolerability between ebastine and placebo groups.
- Incidences of drowsiness and dry mouth were comparable between treatments.
Conclusions:
- Oral ebastine (10 mg daily) is an effective treatment for perennial allergic rhinitis.
- Ebastine demonstrates a favorable tolerability profile for PAR management.